Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis, Oncology, and Pain Management Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EDG2/LPAR1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery (Full-length) | LPAR1 Lentivirus Premade Particles Full-length ORF, HEK293T packaged, high titer (>10⁸ TU/mL). For stable cell line generation preserving native conformation. |
View LPAR1 Products |
| ECD Fusion Protein | LPAR1 N-terminal ECD-Fc Fusion Protein HEK293 expressed, sequence verified, >95% purity, endotoxin <1 EU/μg. For binding and internalization assays. |
View LPAR1 Products |
| Gene Delivery (ORF) | LPAR1 Promise-ORF Clone Codon-optimized for mammalian expression. Custom expression. |
View LPAR1 Products |
| Benchmark Antibody | Anti-LPAR1 Reference Antibody Recombinant monoclonal, suitable for flow cytometry and assay validation. |
View LPAR1 Products |
| Validator | LPAR1 siRNA Set (3 target-specific + 1 control) Sequence verified for knockdown verification and specificity controls. |
View LPAR1 Products |
| Related Target A | LPAR2 (EDG4) Subfamily homolog for selectivity counter-screening. |
View LPAR2 Products |
| Related Target B | LPAR3 (EDG7) Off-target assessment for subfamily cross-reactivity. |
View LPAR3 Products |
| Pathway Partner | ENPP2 (Autotaxin) Upstream LPA-generating enzyme; synergy target for combination therapy. |
View ENPP2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Preserving Native GPCR Conformation & Internalization | Lentivirus-based stable cell lines maintain native glycosylation and multi-spanning membrane structure, enabling calcium flux and internalization assays. |
| Cross-species Translation (Human/Cyno/Mouse) | Ortholog proteins and lentivirus available for human, cynomolgus monkey, and mouse LPAR1 for preclinical efficacy and toxicity studies. |
| Family Selectivity (LPAR1 vs LPAR2/3) | Homolog panel of LPAR1, LPAR2, and LPAR3 proteins and stable cell lines for precise off-target liability assessment. |
| Lack of Validated Controls | Clinical benchmark antibodies and expression-ready ORF clones included for robust assay validation. |
| Specificity Validation (False Positive Elimination) | Validated siRNA with guaranteed knockdown efficiency for specificity checks and negative controls. |
| Functional Validation (Signaling) | Premade LPAR1-overexpressing cell lines validated for calcium mobilization and β‑arrestin recruitment assays. |
Live EDG2/LPAR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EDG2/LPAR1 therapeutics is heavily focused on idiopathic pulmonary fibrosis (IPF) and expanding to systemic sclerosis‑associated interstitial lung disease (SSc‑ILD). Bristol Myers Squibb’s BMS‑986278 is the leading small‑molecule antagonist, progressing in Phase 2/3 trials. Other players such as ARDelyx are exploring oral small molecules for gastrointestinal fibrosis. As first‑generation therapies face selectivity and toxicity hurdles, the next wave includes highly selective allosteric modulators, biased signaling modulators targeting profibrotic Gα12/13 or Gαq pathways, and combination regimens with upstream Autotaxin (ENPP2) inhibition. Monoclonal antibodies are also emerging for localized delivery and improved safety profiles in fibrosis and oncology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | Bristol Myers Squibb (BMS‑986278), ARDelyx | IPF, SSc‑ILD | Selectivity assay (Need LPAR1 vs LPAR2/3 lentivirus cell lines for calcium flux) |
| Monoclonal Antibody / Biologic | Preclinical biotechs | Fibrosis, Solid Tumors | Binding & internalization assay (Need native conformation cell lines and ECD‑Fc protein for SPR) |
| Biased Signaling Modulator | Various biotechs | Pain, NASH | Pathway selectivity assay (Need β‑arrestin vs G‑protein reporter lines) |
| Combination Therapy (ATX + LPAR1) | Academic / Preclinical | Liver Fibrosis | Co‑expression screening (Need LPAR1 and ENPP2/ATX proteins) |
Key Assay Considerations for Best‑in‑Class Development
EDG2/LPAR1 is a complex GPCR requiring cell‑based assays to preserve native conformation. Affinity and residence time must be measured using competitive binding on lentivirus‑stable cell lines. Cross‑species profiling (human/cyno/mouse) is essential for preclinical translation. Biased signaling quantification (β‑arrestin vs G‑protein) enables fine‑tuning of therapeutic efficacy. Family selectivity against LPAR2/3/5/6 must be rigorously evaluated to avoid off‑target cardiovascular and hepatic toxicity. TarMart’s integrated toolkit—lentivirus particles, ECD‑Fc proteins, benchmark antibodies, and validated siRNA—addresses each challenge, enabling a streamlined path from hit identification to IND‑enabling studies.